Perjeta

Product Description

What is PERJETA ( Pertuzumab ) Injection ?

PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

What are the indications and usage?

PERJETA is a HER2/neu receptor antagonist indicated for:

• Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
• Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival.

Limitations of Use: :

• The safety of PERJETA as part of a doxorubicin-containing regimen has not been established.
• The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established.

Hodgkin lymphoma and systemic anaplastic large cell lymphoma are both types of cancer of the white blood cells.

How supplied/storage and handling ?

The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established.

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use.

Keep vial in the outer carton in order to protect from light.